1984
DOI: 10.1007/bf00200051
|View full text |Cite
|
Sign up to set email alerts
|

Virus-augmented delayed hypersensitivity skin tests in gynecological malignancies

Abstract: Cultured human tumor cells of various histologic origins were infected with PR8/A/34 influenza virus. Nonviable crude membrane extracts were derived from the infected and uninfected cells. The extracts were coded and tested for their ability to produce delayed hypersensitivity skin reactions (DHSR) in allogeneic patients with squamous uterine cervical carcinoma, epithelial ovarian carcinoma, and malignant melanoma. Augmented antigen sensitivity to the virus-modified extracts compared with virus alone or to the… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
1
0

Year Published

1986
1986
1995
1995

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 7 publications
(1 citation statement)
references
References 18 publications
0
1
0
Order By: Relevance
“…Sinkovics (2) initially evaluated VO preparations in patients with malignant melanoma and sarcoma. Freedman et al (13)(14)(15)(16) subsequently explored the application of VO to the treatment of gynecologic malignancies. The objectives of these studies were to determine whether labeled leukocytes or lymphocytes obtained from the peripheral blood of patients treated with VO could be utilized to study the trafficking patterns of these lymphocytes in patients undergoing regional treatment with VO.…”
mentioning
confidence: 99%
“…Sinkovics (2) initially evaluated VO preparations in patients with malignant melanoma and sarcoma. Freedman et al (13)(14)(15)(16) subsequently explored the application of VO to the treatment of gynecologic malignancies. The objectives of these studies were to determine whether labeled leukocytes or lymphocytes obtained from the peripheral blood of patients treated with VO could be utilized to study the trafficking patterns of these lymphocytes in patients undergoing regional treatment with VO.…”
mentioning
confidence: 99%